Request Demo
Pharmaceutical Insights
Navigate pharmaceutical trends with our insights on targets, institutional pipelines, clinical advances, and new drugs.
Recent blog posts
9 min read
nL-CHCHD-001 in Amyotrophic Lateral Sclerosis: NCT07095686 Clinical Landscape Report 2026
18 September 2026
NCT07095686 clinical landscape for Amyotrophic Lateral Sclerosis: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
HEC169584 in Metabolic Dysfunction Associated Steatohepatitis: NCT07099118 Clinical Landscape Report 2026
18 September 2026
NCT07099118 clinical landscape for Metabolic Dysfunction Associated Steatohepatitis: endpoints, sponsor, phase, geography, readouts, asset context and develo…
9 min read
SUN-001 in Idiopathic Pulmonary Fibrosis: ACTRN12625000865415 Clinical Landscape Report 2026
18 September 2026
ACTRN12625000865415 clinical landscape for Idiopathic Pulmonary Fibrosis: endpoints, sponsor, phase, geography, readouts, asset context and development white…
9 min read
LY-4256984 in Amyotrophic Lateral Sclerosis: NCT07100119 Clinical Landscape Report 2026
18 September 2026
NCT07100119 clinical landscape for Amyotrophic Lateral Sclerosis: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
XS228 in Amyotrophic Lateral Sclerosis: NCT07118319 Clinical Landscape Report 2026
18 September 2026
NCT07118319 clinical landscape for Amyotrophic Lateral Sclerosis: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Recombinant pegylated human FGF21(Tasly Biopharmaceuticals) in Metabolic Dysfunction Associated Steatohepatitis: NCT07128797 Clinical Landscape Report 2026
18 September 2026
NCT07128797 clinical landscape for Metabolic Dysfunction Associated Steatohepatitis: endpoints, sponsor, phase, geography, readouts, asset context and develo…
9 min read
Recombinant humanized anti-PEAR1 monoclonal antibody(Shanghai Xunyao) in Idiopathic Pulmonary Fibrosis: NCT07121413 Clinical Landscape Report 2026
18 September 2026
NCT07121413 clinical landscape for Idiopathic Pulmonary Fibrosis: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Menstrual blood derived mesenchymal stem cells (Innovative Precision Medicine Group) in Idiopathic Pulmonary Fibrosis: NCT07131150 Clinical Landscape Report 2026
18 September 2026
NCT07131150 clinical landscape for Idiopathic Pulmonary Fibrosis: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Temozolomide in Recurrent Glioblastoma: NCT07138001 Clinical Landscape Report 2026
18 September 2026
NCT07138001 clinical landscape for Recurrent Glioblastoma: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Cromolyn in Amyotrophic Lateral Sclerosis: NCT07142291 Clinical Landscape Report 2026
18 September 2026
NCT07142291 clinical landscape for Amyotrophic Lateral Sclerosis: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
FHND1002 in Amyotrophic Lateral Sclerosis: NCT07138014 Clinical Landscape Report 2026
18 September 2026
NCT07138014 clinical landscape for Amyotrophic Lateral Sclerosis: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
MSC11FCD in Glioblastoma Multiforme: NCT07143812 Clinical Landscape Report 2026
18 September 2026
NCT07143812 clinical landscape for Glioblastoma Multiforme: endpoints, sponsor, phase, geography, readouts, asset context and development white space.